Hypoglycaemia
Hypoglycaemia is a pathological reduction in blood glucose that compromises cerebral function and systemic homeostasis. Unlike hyperglycaemia, which causes damage over time, hypoglycaemia produces immediate physiological threat because glucose is the brain’s primary energy substrate. Even brief reductions in glucose availability can impair neuronal function. Hypoglycaemia can have a rapid onset, exhibit characteristic autonomic and neurological symptoms, and repeated episodes increase risk rather than tolerance.
What You Need to Know
Hypoglycaemia occurs when blood glucose falls below the level required to meet the brain’s metabolic needs. Under normal conditions, glucose homeostasis is maintained through coordinated hormonal responses. As blood glucose declines, insulin secretion is suppressed and counter-regulatory hormones such as glucagon and adrenaline increase hepatic glucose production while limiting peripheral glucose utilisation. These mechanisms protect cerebral glucose supply and prevent neuroglycopenia.
When glucose availability continues to fall despite these defences, neuronal energy failure develops rapidly. The brain relies almost entirely on glucose for energy and has minimal capacity for storage, so even brief reductions impair neuronal metabolism. Reduced glucose delivery disrupts membrane ion gradients and synaptic transmission, leading to altered cognition, behavioural change, seizures, or loss of consciousness.
Several mechanisms commonly contribute to hypoglycaemia:
Excess insulin or insulin secretagogues driving glucose into tissues
Reduced dietary intake or delayed absorption limiting glucose availability
Increased glucose utilisation during exercise, illness, or sepsis
Impaired counter-regulatory hormone responses, particularly in long-standing diabetes
Once compensatory responses are overwhelmed or absent, neurological dysfunction can progress quickly. Early recognition is critical, as prolonged hypoglycaemia can result in irreversible neuronal injury, particularly within vulnerable regions such as the hippocampus and cerebral cortex.
Beyond the Basics
Glucose as an obligatory cerebral fuel
The brain depends almost entirely on circulating glucose to meet its energy needs and has very limited capacity to store or generate alternative fuel under normal conditions. Unlike skeletal muscle or the liver, it cannot draw on substantial local glycogen reserves, so it relies on a continuous supply of glucose from the bloodstream. Neurons use this glucose to produce adenosine triphosphate, the energy currency required to maintain membrane ion gradients, generate action potentials, and support synaptic transmission. These ion gradients are maintained by energy-dependent membrane pumps, particularly the sodium–potassium ATPase pump, which keeps electrical signalling stable.
When blood glucose falls, ATP production declines rapidly. As energy failure develops, ion pumps begin to fail, membrane potentials become unstable, and neuronal communication is disrupted. This state is called neuroglycopenia, meaning the brain is not receiving enough glucose to function normally. Neuroglycopenia produces symptoms such as difficulty concentrating, confusion, irritability, behavioural change, blurred thinking, seizures, and reduced consciousness. Early manifestations reflect functional disturbance rather than immediate structural destruction, which is why symptoms can improve quickly when glucose is restored promptly.
If hypoglycaemia is severe or prolonged, the problem shifts from temporary dysfunction to true cellular injury. Sustained energy failure causes loss of ionic homeostasis, cellular swelling, excitotoxic injury, and eventually neuronal death. Certain regions are especially vulnerable, including the hippocampus, which is important for memory formation, and the cerebral cortex, which supports higher cognitive function. This is why prolonged hypoglycaemia can result in lasting neurological deficits, even after blood glucose is corrected.
Counter-regulatory hormone failure
Protection against falling blood glucose depends on a coordinated set of physiological responses known as the counter-regulatory response. These mechanisms act to restore glucose levels before cerebral function is significantly impaired. Glucagon, released from pancreatic alpha cells, promotes hepatic glycogenolysis and gluconeogenesis. Glycogenolysis is the breakdown of stored glycogen into glucose, while gluconeogenesis is the generation of new glucose from non-carbohydrate substrates such as lactate, glycerol, and amino acids. Together, these processes increase the amount of glucose released into the circulation.
Adrenaline also plays a central role. It stimulates hepatic glucose output, limits peripheral glucose uptake, and produces the autonomic warning symptoms that often alert a person to falling glucose levels. These include tremor, palpitations, sweating, anxiety, and hunger. These symptoms are protective because they prompt behavioural responses, such as eating carbohydrates, before neuroglycopenia becomes severe.
In people with long-standing diabetes, particularly those treated with insulin, these protective mechanisms often deteriorate. One of the earliest defects is impaired glucagon release during hypoglycaemia, meaning the liver does not increase glucose output as effectively. Recurrent episodes also blunt the adrenergic response, so the person experiences fewer or weaker warning symptoms. As these hormonal defences fail, glucose can fall to dangerously low levels before the individual recognises that anything is wrong. This markedly increases the risk of severe hypoglycaemia, requiring assistance from another person or urgent medical treatment.
Hypoglycaemia unawareness and neural adaptation
Repeated hypoglycaemic episodes produce adaptive changes within the brain’s glucose-sensing systems. These changes alter the threshold at which the body detects low glucose and initiates counter-regulatory responses. In practical terms, the brain becomes more efficient at functioning at lower glucose levels for a period of time. This may involve increased glucose transport across the blood–brain barrier and altered neuronal sensitivity to reduced glucose availability.
Although this adaptation may temporarily preserve brain function, it comes at a cost. The autonomic warning symptoms that normally appear early begin to occur later, at lower glucose concentrations, or may not appear at all. This phenomenon is known as hypoglycaemia unawareness. The person therefore loses the usual sequence of early warning signs and may move directly from apparent stability to abrupt neuroglycopenia.
Clinically, this is dangerous because it removes the opportunity for self-correction. Without tremor, palpitations, sweating, or hunger to prompt action, the first noticeable signs may be confusion, inability to communicate, seizure activity, collapse, or coma. Recovery often then depends on external intervention, such as oral glucose from another person, glucagon administration, or intravenous dextrose. Hypoglycaemia unawareness is therefore not simply reduced symptom perception, but a major loss of physiological protection.
Systemic effects beyond the brain
Although the neurological effects of hypoglycaemia are often the most obvious, hypoglycaemia is a systemic physiological stressor rather than a purely cerebral event. Falling glucose activates the sympathetic nervous system and triggers catecholamine release, particularly adrenaline and noradrenaline. This increases heart rate, myocardial contractility, peripheral vasoconstriction, and blood pressure variability. These responses are designed to support glucose mobilisation, but they also increase cardiac workload and myocardial oxygen demand.
In individuals with underlying cardiovascular disease, this sympathetic surge can be particularly harmful. Hypoglycaemia is associated with electrical instability of the myocardium and can increase the risk of cardiac arrhythmias, including potentially life-threatening rhythm disturbances. It may also worsen myocardial ischaemia in susceptible patients by increasing oxygen demand at a time of physiological stress.
The effects are not limited to the heart. Recurrent hypoglycaemia contributes to broader metabolic and inflammatory stress, disrupts normal endocrine regulation, and can impair overall physiological resilience. The observed association between severe or recurrent hypoglycaemia and increased mortality highlights that hypoglycaemia should not be viewed as a minor side effect of treatment. It is a significant systemic disturbance with neurological, cardiovascular, and metabolic consequences, particularly when episodes are frequent, prolonged, or poorly recognised.
Clinical Connections
Early hypoglycaemia commonly presents with autonomic symptoms such as sweating, tremor, hunger, and palpitations due to activation of the sympathetic nervous system. These symptoms serve as an early warning that circulating glucose is falling. As glucose levels decline further, cerebral glucose delivery becomes inadequate and neuroglycopenic features emerge, including confusion, altered behaviour, visual disturbance, seizures, and reduced level of consciousness.
Progression from autonomic to neuroglycopenic symptoms signals increasing physiological risk:
Loss of early adrenergic warning signs due to impaired counter-regulatory responses
Rapid onset of cognitive and behavioural change as neuronal energy failure develops
Increased likelihood of seizures or collapse once cerebral glucose supply is critically reduced
Hypoglycaemia is managed by rapidly restoring blood glucose levels and monitoring response, with treatment guided by the patient’s level of consciousness and BGL.
If conscious and able to swallow: give ~15 g fast-acting carbohydrate (e.g. 150 mL juice, regular soft drink, or glucose tablets), then recheck BGL in 10–15 minutes
Repeat treatment if BGL remains low, and follow with a longer-acting carbohydrate once stable
If reduced consciousness or unable to swallow: administer IV glucose (e.g. 10% or 50%)
If IV access is not available: give glucagon IM or SC
Continue to monitor BGL, observe for recurrence, and escalate if there is no response
Management centres on prompt restoration of glucose availability while identifying and correcting the precipitating cause. Acute treatment reverses neuronal dysfunction, but prevention remains essential. Recurrent hypoglycaemia alters hormonal responses and cerebral adaptation, increasing susceptibility to future episodes and changing symptom patterns over time. Understanding these mechanisms explains why reducing recurrence is as important as treating individual events in limiting long-term neurological and cardiovascular harm.
Concept Check
Why is the brain particularly vulnerable to falling blood glucose levels?
How do counter-regulatory hormones normally protect against hypoglycaemia?
Why does recurrent hypoglycaemia reduce autonomic warning symptoms?
How does hypoglycaemia unawareness increase clinical risk?
Why can hypoglycaemia contribute to cardiac instability?